Incannex Healthcare Soars 30.11% on Sleep Apnea Trial Success

Incannex Healthcare's stock price surged by 30.11% in pre-market trading on May 16, 2025, driven by significant developments in its clinical trials for obstructive sleep apnea.

The company recently completed patient dosing in its Phase 2/3 trial for IHL-42X, a once-daily oral treatment for obstructive sleep apnea. This milestone has generated substantial buzz and optimism among investors, as the successful completion of this phase brings the drug one step closer to potential market approval.

Incannex Healthcare has also provided updates on its clinical program, outlining key upcoming catalysts in the development of IHL-42X. These updates have further fueled investor enthusiasm, as the company continues to make progress in its efforts to address a significant unmet medical need.

The positive sentiment surrounding Incannex Healthcare's sleep apnea drug candidate has been a major driver of its recent stock price surge. As the company continues to advance its clinical trials and provide updates on its progress, investors are closely watching for any further developments that could impact the stock's performance.